Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
Stilgenbauer, Stephan, Prof, Eichhorst, Barbara, Prof, Schetelig, Johannes, Prof, Coutre, Steven, Prof, Seymour, John F, Prof, Munir, Talha, Prof, Puvvada, Soham D, MD, Wendtner, Clemens-Martin, Prof, Roberts, Andrew W, Prof, Jurczak, Wojciech, Prof, Mulligan, Stephen P, Prof, Böttcher, Sebastian, MD, Mobasher, Mehrdad, MD, Zhu, Ming, PhD, Desai, Monali, MD, Chyla, Brenda, PhD, Verdugo, Maria, MD, Enschede, Sari Heitner, MD, Cerri, Elisa, MD, Humerickhouse, Rod, MD, Gordon, Gary, MD, Hallek, Michael, Prof, Wierda, William G, MD
Published in The lancet oncology (01.06.2016)
Published in The lancet oncology (01.06.2016)
Get full text
Journal Article
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
Seymour, John F, Prof, Ma, Shuo, MD, Brander, Danielle M, MD, Choi, Michael Y, MD, Barrientos, Jacqueline, MD, Davids, Matthew S, MD, Anderson, Mary Ann, MBBS, Beaven, Anne W, MD, Rosen, Steven T, Prof, Tam, Constantine S, MD, Prine, Betty, BS, Agarwal, Suresh K, PhD, Munasinghe, Wijith, PhD, Zhu, Ming, PhD, Lash, L Leanne, PhD, Desai, Monali, MD, Cerri, Elisa, MD, Verdugo, Maria, MD, Kim, Su Young, MD, Humerickhouse, Rod A, MD, Gordon, Gary B, MD, Kipps, Thomas J, Prof, Roberts, Andrew W, Prof
Published in The lancet oncology (01.02.2017)
Published in The lancet oncology (01.02.2017)
Get full text
Journal Article
Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments
Agarwal, Suresh K., PhD, DiNardo, Courtney D., MD, Potluri, Jalaja, MD, Dunbar, Martin, DrPH, Kantarjian, Hagop M., MD, Humerickhouse, Rod A., MD, PhD, Wong, Shekman L., PhD, Menon, Rajeev M., PhD, Konopleva, Marina Y., MD, PhD, Salem, Ahmed Hamed, PhD
Published in Clinical therapeutics (01.02.2017)
Published in Clinical therapeutics (01.02.2017)
Get full text
Journal Article
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Wilson, Wyndham H, Prof, O'Connor, Owen A, Prof, Czuczman, Myron S, Prof, LaCasce, Ann S, MD, Gerecitano, John F, MD, Leonard, John P, Prof, Tulpule, Anil, MD, Dunleavy, Kieron, MD, Xiong, Hao, PhD, Chiu, Yi-Lin, PhD, Cui, Yue, PhD, Busman, Todd, MS, Elmore, Steven W, PhD, Rosenberg, Saul H, PhD, Krivoshik, Andrew P, MD, Enschede, Sari H, MD, Humerickhouse, Rod A, MD
Published in The lancet oncology (01.12.2010)
Published in The lancet oncology (01.12.2010)
Get full text
Journal Article